{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T15:18:03Z","timestamp":1793459883447,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Gaucher disease (GD) in children is highly heterogeneous, severe, and particularly devastating in GD type 3 (GD3), which has systemic and neurological involvement. Imiglucerase enzyme replacement therapy is well-established for managing hematovisceral and skeletal manifestations in GD type 1 (GD1). Its long-term impact in GD3 remains underexplored, with evidence limited to small, single-center cohorts and one registry analysis with limited follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This longitudinal analysis used data from the International Collaborative Gaucher Group (ICGG) Gaucher Registry as of January 2023. Children diagnosed with GD1 or GD3 who started imiglucerase before age 18\u2009years and had an intact spleen and at least one baseline and follow-up measurement were included. Linear mixed models were used to evaluate long-term treatment response of hemoglobin, platelet count, liver and spleen volumes, and Z-scores for height, weight, body mass index, and total lumbar spine bone mineral density (BMD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In total, 961 children with GD1 and 236 with GD3 met the inclusion criteria, representing a population with severe disease requiring early imiglucerase therapy at a median age (25\n                      <jats:sup>th<\/jats:sup>\n                      , 75\n                      <jats:sup>th<\/jats:sup>\n                      percentile) of 7.8 (4.3, 12.0) years for GD1 and 1.9 (1.4, 3.4) years for GD3. Significant hematological and visceral improvements were observed within the first 1.5\u2009years of treatment (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001 for all parameters), followed by incremental gains during up to two decades. Height Z-scores increased substantially during the first three years of treatment (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Total lumbar spine BMD Z-scores improved (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This is the largest, most comprehensive global evaluation of long-term imiglucerase therapy in pediatric GD1 and GD3. Despite complex disease burden in GD3, imiglucerase therapy led to marked hematovisceral disease reversal and meaningful growth improvements, closely paralleling responses in GD1. These findings emphasize the importance of early diagnosis and sustained treatment to optimize long-term outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Registration (registry)<\/jats:title>\n                    <jats:p>NCT00358943 (registration date: April 1, 1991).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-026-04282-w","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T08:55:39Z","timestamp":1773305739000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The global impact of imiglucerase therapy in children with Gaucher disease types 1 and 3: a real-world analysis from the International Collaborative Gaucher Group Gaucher Registry"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3447-6421","authenticated-orcid":false,"given":"Pramod K.","family":"Mistry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny L.","family":"Carwile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Andrew","family":"Burrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azza Abdel Gawad","family":"Tantawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Simon","family":"Camelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaya","family":"Ganesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabela","family":"Batsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Gabriela","family":"Perichon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Oliveira-dos-Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie L.","family":"Batista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"4282_CR1","unstructured":"Grabowski GA, Petsko GA, Kolodny EH. Gaucher disease. In: OMMBID: the online metabolic and molecular bases of inherited disease [Internet]. New York, NY: McGraw-Hill Education; 2019 [cited April 28, 2025]. Available at: https:\/\/ommbid.mhmedical.com\/content.aspx?bookid=2709%26;sectionid=225546056."},{"key":"4282_CR2","doi-asserted-by":"crossref","unstructured":"Boddupalli CS, Nair S, Belinsky G, Gans J, Teeple E, Nguyen TH, et al. Neuroinflammation in neuronopathic Gaucher disease: role of microglia and NK cells, biomarkers, and response to substrate reduction therapy. Elife. 2022;11.","DOI":"10.7554\/eLife.79830"},{"key":"4282_CR3","doi-asserted-by":"crossref","unstructured":"Grabowski GA, Zimran A, Ida H. Gaucher disease types 1 and 3: phenotypic characterization of large populations from the ICGG Gaucher Registry. Am J Hematol. 2015;90(Suppl, 1):S12\u20138.","DOI":"10.1002\/ajh.24063"},{"issue":"5","key":"4282_CR4","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1002\/jimd.12235","volume":"43","author":"R Schiffmann","year":"2020","unstructured":"Schiffmann R, Sevigny J, Rolfs A, Davies EH, Goker-Alpan O, Abdelwahab M, et al. The definition of neuronopathic Gaucher disease. J Inherit Metab Dis. 2020;43(5):1056\u201359.","journal-title":"J Inherit Metab Dis"},{"issue":"4","key":"4282_CR5","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s10545-009-9009-6","volume":"33","author":"A Tylki-Szymanska","year":"2010","unstructured":"Tylki-Szymanska A, Vellodi A, El-Beshlawy A, Cole JA, Kolodny E. Neuronopathic Gaucher disease: demographic and clinical features of 131 patients enrolled in the international Collaborative Gaucher group neurological outcomes subregistry. J Inherit Metab Dis. 2010;33(4):339\u201346.","journal-title":"J Inherit Metab Dis"},{"key":"4282_CR6","doi-asserted-by":"crossref","unstructured":"Vellodi A, Tylki-Szymanska A, Davies EH, Kolodny E, Bembi B, Collin-Histed T, et al. Management of neuronopathic Gaucher disease: revised recommendations. J Inherit Metab Dis. 2009.","DOI":"10.1007\/s10545-009-1164-2"},{"issue":"21","key":"4282_CR7","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","volume":"324","author":"NW Barton","year":"1991","unstructured":"Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC, et al. Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher\u2019s disease. NEJM Evid. 1991;324(21):1464\u201370.","journal-title":"NEJM Evid"},{"issue":"1","key":"4282_CR8","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1186\/s13023-022-02517-0","volume":"17","author":"PK Mistry","year":"2022","unstructured":"Mistry PK, Kishnani P, Wanner C, Dong D, Bender J, Batista JL, et al. Rare lysosomal disease registries: lessons learned over three decades of real-world evidence. Orphanet J Rare Dis. 2022;17(1):362.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"4282_CR9","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ymgme.2020.12.295","volume":"132","author":"NJ Weinreb","year":"2021","unstructured":"Weinreb NJ, Camelo JS Jr, Charrow J, McClain MR, Mistry P, Belmatoug N, et al. Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of imiglucerase treatment. Mol Genet Metab. 2021;132(2):100\u201311.","journal-title":"Mol Genet Metab"},{"issue":"4","key":"4282_CR10","first-page":"539","volume":"138","author":"G Altarescu","year":"2001","unstructured":"Altarescu G, Hill S, Wiggs E, Jeffries N, Kreps C, Parker CC, et al. The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher\u2019s disease. J Sport Hist Pediatrics. 2001;138(4):539\u201347.","journal-title":"J Sport Hist Pediatrics"},{"issue":"1","key":"4282_CR11","first-page":"89","volume":"153","author":"O Goker-Alpan","year":"2008","unstructured":"Goker-Alpan O, Wiggs EA, Eblan MJ, Benko W, Ziegler SG, Sidransky E, et al. Cognitive outcome in treated patients with chronic neuronopathic Gaucher disease. J Sport Hist Pediatrics. 2008;153(1):89\u201394.","journal-title":"J Sport Hist Pediatrics"},{"issue":"1\u20132","key":"4282_CR12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ymgme.2016.12.001","volume":"120","author":"A El-Beshlawy","year":"2017","unstructured":"El-Beshlawy A, Tylki-Szymanska A, Vellodi A, Belmatoug N, Grabowski GA, Kolodny EH, et al. Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the international Collaborative Gaucher group Gaucher Registry. Mol Genet Metab. 2017;120(1\u20132):47\u201356.","journal-title":"Mol Genet Metab"},{"key":"4282_CR13","doi-asserted-by":"crossref","unstructured":"Tajima A, Yokoi T, Ariga M, Ito T, Kaneshiro E, Eto Y, et al. Clinical and genetic study of Japanese patients with type 3 Gaucher disease. Mol Genet Metab. 2009.","DOI":"10.1016\/j.ymgme.2009.05.001"},{"issue":"3","key":"4282_CR14","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ymgme.2014.07.022","volume":"113","author":"A Sechi","year":"2014","unstructured":"Sechi A, Deroma L, Dardis A, Ciana G, Bertin N, Concolino D, et al. Long term effects of enzyme replacement therapy in an Italian cohort of type 3 Gaucher patients. Mol Genet Metab. 2014;113(3):213\u201318.","journal-title":"Mol Genet Metab"},{"issue":"10","key":"4282_CR15","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s13312-011-0128-4","volume":"48","author":"A Nagral","year":"2011","unstructured":"Nagral A, Mewawalla P, Jagadeesh S, Kabra M, Phadke SR, Verma IC, et al. Recombinant macrophage targeted enzyme replacement therapy for Gaucher disease in India. Indian Pediatr. 2011;48(10):779\u201384.","journal-title":"Indian Pediatr"},{"issue":"9","key":"4282_CR16","first-page":"653","volume":"44","author":"YL Duan","year":"2006","unstructured":"Duan YL, Zhang YH, Zang Y, Shi HP, Zhang WM, Hu YM. A retrospective study on enzyme replacement therapy in patients with Gaucher disease. Zhonghua Er Ke Za Zhi. 2006;44(9):653\u201356.","journal-title":"Zhonghua Er Ke Za Zhi"},{"issue":"2","key":"4282_CR17","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.braindev.2010.02.005","volume":"33","author":"I Kraoua","year":"2011","unstructured":"Kraoua I, Sedel F, Caillaud C, Froissart R, Stirnemann J, Chaurand G, et al. A French experience of type 3 Gaucher disease: phenotypic diversity and neurological outcome of 10 patients. Brain Dev. 2011;33(2):131\u201339.","journal-title":"Brain Dev"},{"issue":"1","key":"4282_CR18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.7326\/0003-4819-122-1-199501010-00005","volume":"122","author":"GA Grabowski","year":"1995","unstructured":"Grabowski GA, Barton NW, Pastores G, Dambrosia JM, Banerjee TK, McKee MA, et al. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med. 1995;122(1):33\u201339.","journal-title":"Ann Intern Med"},{"issue":"3","key":"4282_CR19","doi-asserted-by":"publisher","first-page":"209","DOI":"10.7863\/jum.1997.16.3.209","volume":"16","author":"D Elstein","year":"1997","unstructured":"Elstein D, Hadas-Halpern I, Azuri Y, Abrahamov A, Bar-Ziv Y, Zimran A. Accuracy of ultrasonography in assessing spleen and liver size in patients with Gaucher disease: comparison to computed tomographic measurements. J Ultrasound Med. 1997;16(3):209\u201311.","journal-title":"J Ultrasound Med"},{"issue":"246","key":"4282_CR20","first-page":"1","volume":"2002","author":"RJ Kuczmarski","year":"2000","unstructured":"Kuczmarski RJ, Ogden CL, Guo SS, Grummer-Strawn LM, Flegal KM, Mei Z, et al. CDC growth charts for the United States: methods and development. Vital Health Stat 11. 2000;2002(246):1\u2013190.","journal-title":"Vital Health Stat 11"},{"key":"4282_CR21","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.bcmd.2016.10.008","volume":"68","author":"M Biegstraaten","year":"2018","unstructured":"Biegstraaten M, Cox TM, Belmatoug N, Berger MG, Collin-Histed T, Vom Dahl S, et al. Management goals for type 1 Gaucher disease: an expert consensus document from the European working group on Gaucher disease. Blood Cells Mol Dis. 2018;68:203\u201308.","journal-title":"Blood Cells Mol Dis"},{"issue":"4 suppl 5","key":"4282_CR22","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1053\/j.seminhematol.2004.07.009","volume":"41","author":"GM Pastores","year":"2004","unstructured":"Pastores GM, Weinreb NJ, Aerts H, Andria G, Cox TM, Giralt M, et al. Therapeutic goals in the treatment of Gaucher disease. Semin Hematol. 2004;41(4 suppl 5):4\u201314.","journal-title":"Semin Hematol"},{"issue":"1","key":"4282_CR23","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.bcmd.2010.10.011","volume":"46","author":"PK Mistry","year":"2011","unstructured":"Mistry PK, Weinreb NJ, Kaplan P, Cole JA, Gwosdow AR, Hangartner T. Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults. Blood Cells Mol Dis. 2011;46(1):66\u201372.","journal-title":"Blood Cells Mol Dis"},{"issue":"5","key":"4282_CR24","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1093\/hmg\/ddx442","volume":"27","author":"LM Panicker","year":"2018","unstructured":"Panicker LM, Srikanth MP, Castro-Gomes T, Miller D, Andrews NW, Feldman RA. Gaucher disease iPSC-derived osteoblasts have developmental and lysosomal defects that impair bone matrix deposition. Hum Mol Genet. 2018;27(5):811\u201322.","journal-title":"Hum Mol Genet"},{"issue":"6","key":"4282_CR25","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1002\/jbmr.3734","volume":"34","author":"D Hughes","year":"2019","unstructured":"Hughes D, Mikosch P, Belmatoug N, Carubbi F, Cox T, Goker-Alpan O, et al. Gaucher disease in bone: from pathophysiology to practice. J Bone Min Res. 2019;34(6):996\u20131013.","journal-title":"J Bone Min Res"},{"issue":"45","key":"4282_CR26","doi-asserted-by":"publisher","first-page":"19473","DOI":"10.1073\/pnas.1003308107","volume":"107","author":"PK Mistry","year":"2010","unstructured":"Mistry PK, Liu J, Yang M, Nottoli T, McGrath J, Jain D, et al. Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage. Proc Natl Acad Sci USA. 2010;107(45):19473\u201378.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"4282_CR27","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s00586-011-1983-3","volume":"21","author":"A Dimeglio","year":"2012","unstructured":"Dimeglio A, Canavese F. The growing spine: how spinal deformities influence normal spine and thoracic cage growth. Eur Spine J. 2012;21(1):64\u201370.","journal-title":"Eur Spine J"},{"issue":"5","key":"4282_CR28","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/imj.14156","volume":"49","author":"A Mehta","year":"2019","unstructured":"Mehta A, Kuter DJ, Salek SS, Belmatoug N, Bembi B, Bright J, et al. Presenting signs and patient co-variables in Gaucher disease: outcome of the Gaucher earlier diagnosis consensus (GED-C) Delphi initiative. Intern Med J. 2019;49(5):578\u201391.","journal-title":"Intern Med J"},{"issue":"2","key":"4282_CR29","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ymgme.2021.01.002","volume":"132","author":"EC Daykin","year":"2021","unstructured":"Daykin EC, Ryan E, Sidransky E. Diagnosing neuronopathic Gaucher disease: new considerations and challenges in assigning Gaucher phenotypes. Mol Genet Metab. 2021;132(2):49\u201358.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"4282_CR30","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1093\/brain\/awac379","volume":"146","author":"R Schiffmann","year":"2023","unstructured":"Schiffmann R, Cox TM, Dedieu JF, Gaemers SJM, Hennermann JB, Ida H, et al. Venglustat combined with imiglucerase for neurological disease in adults with Gaucher disease type 3: the LEAP trial. Brain. 2023;146(2):461\u201374.","journal-title":"Brain"},{"issue":"4","key":"4282_CR31","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/ana.410420412","volume":"42","author":"R Schiffmann","year":"1997","unstructured":"Schiffmann R, Heyes MP, Aerts JM, Dambrosia JM, Patterson MC, DeGraba T, et al. Prospective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher\u2019s disease. Ann Neurol. 1997;42(4):613\u201321.","journal-title":"Ann Neurol"},{"issue":"4","key":"4282_CR32","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1111\/j.1365-2141.1993.tb03224.x","volume":"85","author":"A Zimran","year":"1993","unstructured":"Zimran A, Hadas-Halpern I, Zevin S, Levy-Lahad E, Abrahamov A. Low-dose high-frequency enzyme replacement therapy for very young children with severe Gaucher disease. Br J Haematol. 1993;85(4):783\u201386.","journal-title":"Br J Haematol"},{"issue":"3","key":"4282_CR33","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/j.1651-2227.2006.tb02232.x","volume":"95","author":"A Erikson","year":"2006","unstructured":"Erikson A, Forsberg H, Nilsson M, Astrom M, Mansson JE. Ten Years\u2019 experience of enzyme infusion therapy of Norrbottnian (type 3) Gaucher disease. Acta Paediatr. 2006;95(3):312\u201317.","journal-title":"Acta Paediatr"},{"key":"4282_CR34","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3389\/fncel.2015.00028","volume":"9","author":"R Sankowski","year":"2015","unstructured":"Sankowski R, Mader S, Valdes-Ferrer SI. Systemic inflammation and the brain: novel roles of genetic, molecular, and environmental cues as drivers of neurodegeneration. Front Cell Neurosci. 2015;9:28.","journal-title":"Front Cell Neurosci"},{"key":"4282_CR35","unstructured":"Fattahi N, Belinsky G, Zhang B, Klinger K, Mistry PK, LB-23 NS. Outcomes of ERT\/SRT monotherapy and combination therapy in neuronopathic Gaucher disease mouse model suggest transfer of peripheral ERT to the brain. 20th Annual WORLDSymposium. San Diego, CA2024: Feb 6."},{"issue":"2","key":"4282_CR36","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ymgme.2006.09.003","volume":"90","author":"K Starzyk","year":"2007","unstructured":"Starzyk K, Richards S, Yee J, Smith SE, Kingma W. The long-term international safety experience of imiglucerase therapy for Gaucher disease. Mol Genet Metab. 2007;90(2):157\u201363.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"4282_CR37","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s40264-021-01125-4","volume":"45","author":"SF Tsang","year":"2022","unstructured":"Tsang SF, Pandya S, Barakov K, Keutzer J, Lewis G, Ross L, et al. Use of identical INN \u201cimiglucerase\u201d for different Drug products: Impact analysis of adverse events in a proprietary global safety database. Drug Saf. 2022;45(2):127\u201336.","journal-title":"Drug Saf"},{"issue":"1","key":"4282_CR38","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1182\/blood.V90.1.43.43_43_48","volume":"90","author":"E Ponce","year":"1997","unstructured":"Ponce E, Moskovitz J, Grabowski G. Enzyme therapy in Gaucher disease type 1: effect of neutralizing antibodies to acid beta-glucosidase. Blood. 1997;90(1):43\u201348.","journal-title":"Blood"},{"issue":"6","key":"4282_CR39","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1182\/blood.V93.6.2081.406k07_2081_2088","volume":"93","author":"M Rosenberg","year":"1999","unstructured":"Rosenberg M, Kingma W, Fitzpatrick MA, Richards SM. Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration. Blood. 1999;93(6):2081\u201388.","journal-title":"Blood"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04282-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04282-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04282-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:49:06Z","timestamp":1781639346000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04282-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4282"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04282-w","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]},"assertion":[{"value":"7 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval of the Registry data collection process at participating institutions includes institutional review boards or ethics committees and patient informed consent, as dictated by local policies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. This manuscript does not contain any individual person\u2019s data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Pramod K. Mistry was a principal investigator on the Sanofi-sponsored ENGAGE clinical trial of eliglustat, has received research and travel support from Sanofi. Thomas Andrew Burrow has received research funding, travel reimbursement, and payment for advisory services from Sanofi and Takeda. Azza Abdel Gawad Tantawy has received honoraria for participating as consultant in speakers\u2019 bureau and advisory boards from Sanofi. Jose Simon Camelo has received honoraria for consultation and advisory board participation from Sanofi, and has received educational and travel support from Sanofi. Jaya Ganesh has received research funding, honoraria and travel support from Sanofi. Jenny L. Carwile, Isabela Batsu, Maria Gabriela Perichon, Antonio Oliveira-dos-Santos, and Julie L. Batista are Sanofi employees and may hold stock in the company.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"123"}}